The drug voxelotor (commercially known as Oxbryta) has been approved by the US Food
and Drug Administration for the treatment of sickle cell disease. It is known to reduce …

The hallmark of sickle cell disease is the polymerization of sickle haemoglobin due to a point
mutation in the β‐globin gene (HBB). Under low oxygen saturation, sickle haemoglobin …

The pathology of sickle cell disease is caused by polymerization of the abnormal
hemoglobin S upon deoxygenation in the tissues to form fibers in red cells, causing them to …

Sickle Cell Disease results from a point mutation on the beta subgroups of hemoglobin.
When hemoglobin releases its four ligands it changes from a relaxed (R) structure to a tense …

Although hundreds of different hemoglobin variants have now been identified,
polymerization seems to be a unique property of HbS. 1 Polymerization has been …

The importance of finding the structure of the deoxy-Hb S fiber resides in the information
about the intermolecular interactions that stabilize the fiber struc-ture. With this knowledge, it …

Sickle cell anemia is an inherited genetic disorder arising from a point mutation in the $\beta
$-globin gene that leads to the replacement of Glu by Val at the sixth position of the $\beta …

In the past two decades, chemical modifiers of hemoglobin have contributed to our
understanding of the molecular disease-sickle cell anemia. These modifiers are of two types …

The issue of treating sickle cell disease with drugs that increase hemoglobin oxygen affinity
has come to the fore with the US Food and Drug Administration approval in 2019 of …

Sickle cell anemia is a genetic disease in which the erythrocytes have lost their diskoid
shape (1) and their pliability because of the intracellular aggregates of hemoglobin S that …